Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting

doi:10.4292/wjgpt.v9.i1.8

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6429)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

338

WORD

246

HTML

2728

Figures (1-1)

257

Tables (1-1)

302

Sum=3871

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1048

Download

1510

Sum=2558

Feb 6, 2018 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Pharmacol Ther. Feb 6, 2018; 9(1): 8-13
Published online Feb 6, 2018. doi: 10.4292/wjgpt.v9.i1.8

Open in New Tab Full Size Figure Download Figure

Figure 1 Percentage of inflammatory bowel disease (A), Crohn’s disease (B), and ulcerative colitis (C) patients on combination therapy. Y axis: Percentage of infusion patients receiving combination therapy (0-100%); X axis: Year for which data is being reported (2002-2014). A: Percentage of inflammatory bowel disease patients receiving combination therapy over time; B: Percentage of Crohn’s disease patients receiving combination therapy over time; C: Percentage of ulcerative colitis patients receiving combination therapy over time.

Citation: Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS. Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. World J Gastrointest Pharmacol Ther 2018; 9(1): 8-13
URL: https://www.wjgnet.com/2150-5349/full/v9/i1/8.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v9.i1.8